RCUS (Arcus Biosciences) Quality Rank


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $30.33
GF Value $13.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Arcus Biosciences Quality Rank Related Terms

RCUS
46GF Score
Arcus Biosciences Inc RCUS
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $30.33 is trading 126.2% above its estimated GF Value™ of $13.41. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • Quality Rank:
  • GF Value™: $13.41 vs. price of $30.33 (126.2% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$30.33
Price
$13.41
GF Value